




Figure S5. Diagnostic performance of the downregulated circulating miRNA signature across cancer types and external validation. (A) Cross-cancer ROC analysis of the five-miRNA downregulated signature (hsa-miR-1976, hsa-miR-3195, hsa-miR-4639-5p, hsa-miR-660-3p, and hsa-miR-6741-3p) in the GSE211692 multicancer dataset, demonstrating variable discriminative performance across different cancer types. (B) External validation of the downregulated miRNA signature in the independent GSE73002 dataset comprising 1,280 breast cancer patients and 2,836 non-cancer controls.